Compare Palantir Technologies Inc (PLTR) vs Summit Therapeutics Inc (SMMT) Price & Performance

Palantir (PLTR) trades at $132.62, up 0.18% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.33 exceeding expectations. Revenue grew to $4.48 billion in 2025, and net income surged to $1.63 billion, reflecting robust profitability. Analyst sentiment is mixed, with a consensus price target of $185.75 and 46% of analysts rating it a Buy.

Outlook: PLTR's accelerating revenue growth and expanding margins support long-term upside, but high valuation multiples (P/E 151.52, P/S 66.33) pose risks if growth slows. Key catalysts include continued AI adoption and execution on guidance. Risks include competitive pressures and market volatility. The stock offers growth potential but requires tolerance for premium valuation and earnings sensitivity.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.